The Effects of Oxytocin on Complex Social Cognition in Autism Spectrum Disorders
The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2010 by Bartz, Jennifer, Ph.D..
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
Bartz, Jennifer, Ph.D.
Information provided by:
Bartz, Jennifer, Ph.D.
ClinicalTrials.gov Identifier:
NCT01183221
First received: August 12, 2010
Last updated: August 13, 2010
Last verified: August 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study examines the effects of oxytocin on complex social cognition in adults with autism spectrum disorders. Participants receive a one-time administration of intranasal oxytocin (or placebo) and perform an empathic accuracy task, a novel and ecologically valid measure of complex social cognition, in conjunction with functional magnetic resonance imaging (fMRI). We will investigate the effects of oxytocin (versus placebo) on the behavioral and neural correlates of empathic accuracy.
| Condition | Intervention |
|---|---|
|
Autism ASD |
Drug: Syntocinon |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Pharmacodynamics Study Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Investigator, Outcomes Assessor) Primary Purpose: Basic Science |
| Official Title: | The Effects of Oxytocin on Complex Social Cognition in Autism Spectrum Disorders |
Resource links provided by NLM:
Further study details as provided by Bartz, Jennifer, Ph.D.:
Primary Outcome Measures:
- Empathic accuracy performance [ Time Frame: 45 minutes after drug/placebo administration ] [ Designated as safety issue: No ]
- fmri BOLD response during empathic accuracy task [ Time Frame: 45 minutes after oxytocin/placebo administration ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 35 |
| Study Start Date: | June 2010 |
| Estimated Study Completion Date: | August 2011 |
| Estimated Primary Completion Date: | August 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: placebo spray |
Drug: Syntocinon
One dose of 24 IU (3 sprays/nostril)
|
Eligibility| Ages Eligible for Study: | 18 Years to 45 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- In good physical health
- Meet criteria for ASD according to psychiatric interview using the Diagnostic and Statistic Manual, Fourth Edition (DSM-IV)
- Must be a history of developmental delay
- Must meet full criteria for ASD on the Autism Diagnostic Interview- Revised (ADI-R) on either the social or communication domains and within two points on other domain (only if parent available for interview)
- Must meet full criteria for ASD on the Autism Diagnostic Observation Schedule- Generic (ADOS-G) on the social domain. Meeting for ASD on the communication domain and total domain is not necessary
- Must have a verbal IQ greater than 75, as measured by the Wechsler Adult Intelligence Scale- Fourth Edition (WAIS- III). Intelligence testing performed at other sites or through another protocol at this site within the past year will also be accepted
- Capability of performing experimental tasks (i.e. can read and understand task instructions, cooperate with procedures)
- Informed consent and capacity
- Female participants must remain on birth control for the duration of the study
Exclusion Criteria:
- Participants with any primary psychiatric diagnosis at screening
- Participants with a medical history of neurological disease, including, but not limited to, epilepsy/seizure disorder (except simple febrile seizures), movement disorder, tuberous sclerosis, fragile X, and any other known genetic syndromes, or known abnormal MRI/structural lesion of the brain
- Participants who are pregnant, who gave birth in the last six months, or who are currently breastfeeding
- Participants with a medical condition that might interfere with the conduct of the study, confound interpretation of the study results, or endanger their own well-being
- Participants with evidence or history of malignancy or any significant hematological endocrine, cardiovascular (including rhythm disorder), respiratory, renal, hepatic, gastrointestinal disease, or other major medical conditions
- Participants taking psychoactive medication(s) (e.g., stimulants, antidepressants, antipsychotics, antiepileptics, anxiolytics, clondine)
- Participants who, in the Investigator's opinion, might not be suitable for the study
- Participants who are involved in another study whose procedures could influence performance in the current study
- Female participants who do not stay on birth control for the duration of the study
- Participants who have a known contraindication to the MRI scan: including sever claustrophobia or any kind of metal implant in the body
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01183221
Contacts
| Contact: Jessica Zweifach, M.S.T. | 212.241.2826 |
Locations
| United States, New York | |
| Mount Sinai School of Medicine - Seaver Autism Center for Research and Treatment | Recruiting |
| New York, New York, United States, 10029 | |
| Contact: Jessica Zweifach, M.S.T. 212-241-2826 jessica.zweifach@mssm.edu | |
| Principal Investigator: Jennifer Bartz, P.h.D. | |
Sponsors and Collaborators
Bartz, Jennifer, Ph.D.
Investigators
| Principal Investigator: | Jennifer Bartz, P.h.D. | Mount Sinai School of Medicine |
More Information
No publications provided
| Responsible Party: | Jennifer Bartz, Ph.D., Mount Sinai School of Medicine |
| ClinicalTrials.gov Identifier: | NCT01183221 History of Changes |
| Other Study ID Numbers: | 09-0857 |
| Study First Received: | August 12, 2010 |
| Last Updated: | August 13, 2010 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Autistic Disorder Child Development Disorders, Pervasive Mental Disorders Diagnosed in Childhood Mental Disorders Oxytocin |
Oxytocics Reproductive Control Agents Physiological Effects of Drugs Pharmacologic Actions Therapeutic Uses |
ClinicalTrials.gov processed this record on May 23, 2013